Amylyx Pharmaceuticals Inc 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period endedMarch 31,2025OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from ___________________ to ___________________Commission File Number:001-41199 Amylyx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) 46-4600503(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) 43 Thorndike St. 02141(Zip Code) (617)682-0917 (Registrant’s telephone number, including area code)Not Applicable (Former name, former address and former fiscal year, if changed since last report) Title of each classTradingSymbol(s)Name of each exchange on which registeredCommon Stock, $0.0001 par value per shareAMLXNasdaqGlobal Select Stock Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of April 28, 2025, the registrant had89,141,087shares of common stock, $0.0001 par value per share, outstanding. AMYLYX PHARMACEUTICALS, INC.QUARTERLY REPORT ON FORM 10-QFOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 Table of Contents PART I.FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of OperationsCondensed Consolidated Statements of Comprehensive LossCondensed Consolidated Statements of Stockholders’ EquityCondensed Consolidated Statements of Cash FlowsNotes to Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II.OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/amylyx to distribute materialinformation. Our financial and other material information is routinely posted to and accessible on the Investors section of ourwebsite, available at www.amylyx.com. Investors are encouraged to review the Investors section of our website because we maypost material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessedthrough our website or our LinkedIn page is not incorporated into, and does not form a part of, this Quarterly Report on Form 10-Q. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements which are made pursuantto the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E ofthe Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical factscontained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements byterminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,”“predict,” “project,” “should,” “target,” “would” or the negative of these terms or other comparable terminology. These statementsare not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements inthis Quarterly Report include, but are not limited to, express or implied statements about